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Abstract
Background:  Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), infects
approximately 2 billion people worldwide and is the leading cause of mortality due to infectious
disease. Current TB therapy involves a regimen of four antibiotics taken over a six month period.
Patient compliance, cost of drugs and increasing incidence of drug resistant M. tuberculosis strains
have added urgency to the development of novel TB therapies. Eradication of TB is affected by the
ability of the bacterium to survive up to decades in a dormant state primarily in hypoxic granulomas
in the lung and to cause recurrent infections.
Methods:  The availability of M. tuberculosis genome-wide DNA microarrays has lead to the
publication of several gene expression studies under simulated dormancy conditions. However, no
single model best replicates the conditions of human pathogenicity. In order to identify novel TB
drug targets, we performed a meta-analysis of multiple published datasets from gene expression
DNA microarray experiments that modeled infection leading to and including the dormant state,
along with data from genome-wide insertional mutagenesis that examined gene essentiality.
Results: Based on the analysis of these data sets following normalization, several genome wide
trends were identified and used to guide the selection of targets for therapeutic development. The
trends included the significant up-regulation of genes controlled by devR, down-regulation of
protein and ATP synthesis, and the adaptation of two-carbon metabolism to the hypoxic and
nutrient limited environment of the granuloma. Promising targets for drug discovery were several
regulatory elements (devR/devS, relA, mprAB), enzymes involved in redox balance and respiration,
sulfur transport and fixation, pantothenate, isoprene, and NAD biosynthesis. The advantages and
liabilities of each target are discussed in the context of enzymology, bacterial pathways, target
tractability, and drug development.
Conclusion: Based on our bioinformatics analysis and additional discussion of in-depth biological
rationale, several novel anti-TB targets have been proposed as potential opportunities to improve
present therapeutic treatments for this disease.
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Background
Mycobacterium tuberculosis, the causative agent of tubercu-
losis (TB), kills more than 2 million people per year and
has infected an estimated 2 billion people worldwide. It is
the leading cause of mortality due to infectious disease
[1]. The host immune response to aerosol infection is to
quarantine M. tuberculosis in a structure called a granu-
loma which halts replication of the bacillus and sup-
presses the immediate threat of active infection [2].
However, granuloma associated M. tuberculosis bacterium
can switch to a dormant or non-replicative state and suc-
cessfully evade any immune response for decades post-
initial infection [3]. As the host immune system falters, M.
tuberculosis returns to replication mode, which leads to the
recurrence of active infection. Thus current TB therapy to
fight off active disease requires a strictly monitored treat-
ment period or DOTS (directly observed treatment, short
course) lasting up to six months and involving four differ-
ent drugs: isoniazid, rifampicin, pyrazinamide, and
ethambutol [4-6]. Patient compliance with this prolonged
therapeutic regime is an important concern. Moreover,
prolonged exposure to drugs has likely been an important
factor behind increasing reports of anti-biotic resistant
bacterium [7]. The lack of well-defined targets specific to
dormancy phase M. tuberculosis has been a major obstacle
in the development of effective short-course therapies.
A number of studies have attempted to develop in vitro
and in vivo models of non-replicating, dormant phase M.
tuberculosis. These can be grouped into four main types:
hypoxia, starvation, macrophages, and murine infection.
Each system mimics some of, but not the entire, clinical
situation. The Wayne model (slowly stirred, sealed cul-
tures with a defined air-space to medium ratio) [8] cap-
tures the presumed hypoxic nature of the granuloma, but
lacks the effect of the immune response, macrophage
phagocytocis, and eventual release to the extracellular
milieu. The starvation models are not hypoxic and may
not capture the unbalanced diet in the granuloma. The
macrophage phagocytosis experiments show the early
adaptation to the host immune response, but do not
address the long term metabolic changes. While the
murine model replicates many facets of the human
immune response [9], mice do not show well-formed
granulomas and lack the caseous, necrotic centers charac-
teristic of human infection [10]. None of these models
fully capture the heterogeneity of the granuloma, with a
gradient of active and inactive/dead immune cells, oxy-
genation, and nutrients.
DNA microarrays have been used to determine the com-
plete transcriptional response of M. tuberculosis cultured in
each of these experimental models. In addition to the dor-
mancy models, DNA microarrays have also been
employed to do genome-scale knockout experiments
using saturating transposon insertion mutagenesis.
Mutants have been profiled for the ability to grow in vitro,
in mouse macrophages, and in vivo mouse models [11-
14]. In these experiments genes containing (presumably
inactivating) insertions are selected for the ability to grow.
A disrupted gene that inhibits growth yields a decreased
signal on the microarray compared to the genomic con-
trol. In the absence of suitable gene inactivation studies
for the dormant phase, the phenotypic effects of gene
knock-outs on growth phase M. tuberculosis seems to be
the best indicator of gene essentiality from a drug target
perspective.
Here we present a novel and comprehensive meta-analysis
of the M. tuberculosis gene expression and gene disruption
microarray data sets. In the absence of a perfect experi-
mental model we chose a consensus approach and com-
bined the different analyses together into a single
database. Recently, Hasan et al. of the pharmaceutical
company, Novartis, described an in-house software tool
for in silico prioritizing of genomic drug targets in patho-
gens and illustrated its use on M. tuberculosis [15]. Using
this tool, they provided three lists based on different pri-
oritization criteria for: 1) genes associated with critical
metabolic reactions (chokepoints) unique to M. tuberculo-
sis; 2) genes highly specific to the Actinobacter (the taxo-
nomic class of bacteria inclusive of M. tuberculosis) and
absent from other gut flora and 3) genes potentially
important in maintaining persistence. The latter criterion
is the most critical clinical need for TB treatment, and
both Hasan's et al. study and ours use several similar pub-
lished gene expression and essential data-sets to approach
the identification of M. tuberculosis persistence targets.
However, GlaxoSmithKline experiences in developing
novel antibacterials from a genomics-driven target-based
approach have shown the importance of multiple analysis
perspectives and the need to substantiate initial bioinfor-
matics target identifications with additional biological
rationale [16]. Therefore, while encouraged that several
potential targets presented here are also substantiated by
earlier computational studies using different approaches,
we feel it is important to further extend and rationalize in
silico target validation with current knowledge on the biol-
ogy, biochemistry and disease pathology of M. tuberculo-
sis. Thus, we have tried to provide such additional
rationale when evaluating those targets from our priori-
tized list that are the most promising candidates for con-
certed drug development programs.
Results
Figure 1 shows a flowchart of our approach to utilize the
microarray data sets to identify putative gene targets in
non-replicative M. tuberculosis. Table 1 shows the data sets
collected in the first step. Since the experimental condi-
tions in the dormancy models were quite varied (e.g. 24 hBMC Infectious Diseases 2007, 7:84 http://www.biomedcentral.com/1471-2334/7/84
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of starvation in culture media to 4 weeks in whole mice),
the expression results for each gene were normalized (Fig.
1, Step 2). A zero to five scoring system was developed
based upon two criteria. The first criterion was the overall
relevance of the experimental conditions to persistance in
the granuloma. The mouse macrophage and whole ani-
mals studies model the immediate response of M. tubercu-
losis to immune attack and long term survival in the host.
The granuloma itself is characterized by avascularization
and necrosis which have been modeled by the hypoxic
and starvation conditions. The maximum score for a par-
ticular experimental dataset was adjusted based on poten-
tial relevance to the clinical occurrence of dormancy phase
M. tuberculosis infections. For studies with multiple time
series sampling, increasing weight was given to later time-
point samples. The second criteria involved the rank order
of gene expression in a particular study which allowed for
cross-study comparsions (See Table 1 and Methods for
details on the scoring scheme). Down-regulated expres-
sion was scored the same as up-regulated expression
except that negative values were used to easily separate the
two sets of results. (Some genes show significant scores in
both the up-regulated and down-regulated data sets. This
is not surprising considering the variation among studies
in experimental situation and the number of time-
points.) The knockout experiments were similarly scored
by rank order of effect on growth, except that genes having
no effect were scored as zero.
In Step 3 scores for each gene in each of the experimental
conditions were collected into a Microsoft Access data-
base. Reference fields were added to facilitate prioritiza-
tion, such as the Refseq ID, Genbank function, Genbank
note, Tuberculist classification, and KEGG and Sanger
Center links. These data are available in Additional file 1.
There are two important characteristics of this meta-anal-
ysis: i) in order for a gene to score well it must be in the
top quarter of highly induced genes across several experi-
mental models of dormancy and ii) the expression levels
for the highest expressing genes are attenuated. The latter
item has the effect of avoiding the situation where a very
large fold increase in one experiment dwarfs all other
results. The first point is illustrated by the intersection of
the top 400 genes (~10% of the genome) from the
hypoxia, starvation, and in vivo murine models, shown in
Fig. 2. The great majority of the high scoring genes come
from the subset where two or three of the groups intersect.
By combining the data from different models, a consensus
view can reached about the particular genes and pathways
most critical for survival in the dormant state.
Multi-gene trends
Figure 3 shows a comparison of the functional classes [17]
of the up-regulated and down-regulated genes to the
whole genome. The proportion of genes in the top 10% of
up or down-regulated genes was divided by the propor-
tion of that functional class in the entire genome and the
ratio is plotted. The following sections highlight differen-
tial changes in particular functional classes shown in Fig.
3 as well as other multi-gene expression results that
impacted the selection of therapeutic targets.
Table 1: Sources, experimental models, and scoring criteria for Mycobacterium tuberculosis DNA microarray gene expression and 
genome-wide gene knock-out (growth phase essentiality) data used in this study.
Reference Experimental model Timepoint: Maximum scorea
Betts et al., 2002 [116] Starvation under controlled O2 96 h: 3
24 h: 2
4 h: 1
Hampshire et al., 2004 [30] Nutrient depletion under controlled O2 62 and 75 d: 5
49 d: 4
18 d: 2
Muttucumaru et al., 2004 [115] Wayne model of hypoxia [8] 14 d (NRP-2): 4
7 d (NRP-1): 2
Voskuil et al. 2004 [31] Wayne model of hypoxia [8] 30 and 80 d: 5
14 and 20 d: 4
10 and 12 d: 3
6 and 8 d: 2
Schnappinger et al. 2003 [29] Infection of mouse macrophages, +/- γ-INF 24 and 48 h: 5
Karakousis et al., 2004 [117] Hollow fiber subcutaneous implant in mice 10 d: 3
Talaat et al., 2004 [118] Infection of mice. MTB harvested from lungb 28 d: 3
Sassetti et al. 2003a [13] TraSH mutated libraries grown on solid media 14 d:5
Rengarajan et al. 2005 [12] Infection of mouse macrophages, +/- γ-INF 
with TraSH mutated libraries of M. tuberculosis
7 d: 5
Sassetti et al. 2003b [14] C57BL/6J mice infected with TraSH mutated 
libraries of M. tuberculosis
7, 14, 28 and 56 d: 5
Footnotes
aMaximum score based on relevance as a dormancy model.
bRatio of M. tuberculosis from Balb/c lung to MTB in aerated culture for 28 d.BMC Infectious Diseases 2007, 7:84 http://www.biomedcentral.com/1471-2334/7/84
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devR regulon
There is significant experimental evidence that the tran-
scriptional regulator devR (also called dosR) is a key factor
in the metabolic shift-down to non-replicative persistence
(see Discussion). Based on the 20 nt consensus sequence
of  devR  and microarray expression results, two studies
have identified 53 genes that appear to be induced in
response to devR  activation [18,19]. The analysis here
shows 81% of the 53 genes in the devR regulon are in the
top 5% of highest scoring genes, confirming the impor-
tance of this regulatory element in dormancy under a vari-
ety of experimental conditions (see Additional file 2).
Only up-regulated genes were extracted from the data sets
[18,19] so it is expected that these 53 genes show higher
than average up-regulation scores (see Kendall [20] and
Ohno [21] for analyses that included genes down-regu-
lated by devR). Fig. 4A shows a comparison of the expres-
sion pattern for the entire genome and the devR regulon.
While the 53 genes regulated by devR appear to play an
important role in dormancy, nearly 60% of the genes do
not have an annotated function. In order to gain some
insight into the genes regulated by this system, we
searched against INTERPRO (version 12.0) and the COGS
database [22,23]. While some of the assignments are spec-
ulative, (i.e. based on partial overlap with a domain of
known function [24]) several useful clues emerge. Eleven
genes are involved in carbohydrate and fatty acid metabo-
lism, and eight genes function in electron transfer. We
suggest these genes reflect the biased nutrient pool and
lack of oxygen, requiring altered pathways for biosynthe-
sis and to generate oxidizable metabolites and utilization
of other terminal electron acceptors. The occurrence of
four transporters also indicates a limited nutrient pool.
Among the other genes of the devR  regulon, only two
genes alter translation compared with possibly seven tran-
scriptional regulators. This makes the devR regulon even
more significant when one considers the cascading signal
that is produced. These and the other regulators (36 of the
190 total are in the top 10%) show that M. tuberculosis has
Ratio of the number of genes in the highest-scoring fraction  (top 10%) to the number in the entire genome, for each clas- sification described in Cole, et al. [17] Figure 3
Ratio of the number of genes in the highest-scoring fraction 
(top 10%) to the number in the entire genome, for each clas-
sification described in Cole, et al. [17]. Ratios greater than 1 
indicate that the genes are over-represented in the highest-
scoring fraction relative to their representation in the whole 
genome.
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Flowchart of the process used to generate the prioritized list  of tractable therapeutic targets Figure 1
Flowchart of the process used to generate the prioritized list 
of tractable therapeutic targets.
Step 1. Collect genome-wide microarray experiments that model clinical dormancy
Step 2. Normalize experimental results based on rank order of
microarray ratios and relevance to clinical dormancy
Step 3. Construct database with gene annotation, links to external
resources, normalized microarray scores
Step 4. Develop prioritized list of therapeutic targets based on
microarray scores, biochemical rationale, homology to human genes, 
target tractability, and prior knowledge
Overlap of the top 400 highest-scoring genes (~10% of the  genome) from each of the three types of experimental mod- els of dormancy Figure 2
Overlap of the top 400 highest-scoring genes (~10% of the 
genome) from each of the three types of experimental mod-
els of dormancy. Murine refers to M. tuberculosis cells iso-
lated from mouse macrophages, subcutaneous hollow fiber, 
and lung.
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to make global changes to achieve a dormant state. There
are several genes involved in nucleotide biosynthesis
despite the fact that the genome has been replicated prior
to entry into the non-replicative state [25]. This can be
rationalized by the need to make repairs to maintain the
integrity of the genome over decades [26]. The signal from
the expression experiments for the universal stress pro-
teins (USPs) is very strong: six of the eight USPs are part of
the devR regulon, and five of those are in the top 5% of up-
regulated genes.
Only six of the 53 genes have an effect on growth in the
gene disruption experiments (TraSH), supporting the idea
that their main role is in shifting to and maintaining the
non-replicative state. DevS, a regulator of devR (see below)
inhibits growth in vitro [13] and significantly in the mouse
macrophage model [14], consistent with the response to
nitric oxide [18], Disruption of one of the USPs inhibits in
vitro growth [13]; the others had no effect. The gene with
the highest growth inhibition score (9.4) was Rv2004c.
This gene has a partial overlap and low similarity to glu-
conate kinase, but is highly similar to COG2187, a con-
served bacterial domain of unknown function.
C2 metabolism
Fig. 3 shows modest changes in the proportion of genes
involved in intermediary metabolism and respiration. We
interpret this to mean M. tuberculosis has kept a portion of
its metabolic repertoire intact to adapt to hypoxia and a
biased nutrient supply. Up-regulation of genes in C2
metabolism, especially enzymes that maintain redox bal-
ance, utilize alternate terminal electron acceptors, or han-
dle the increased two-carbon flux point to these proteins
as particularly important in the metabolic alterations
made for survival in the hypoxic granuloma.
Downregulation of ATP synthesis
Consistent with previous work and analysis [9,27] the
data here shows a strong down-regulation of the F1-FO
ATP synthase (see Additional file 3), a likely consequence
of hypoxia and the utilization of other terminal electron
acceptors. It thus seems probable that ATP is a scarce
resource in the non-replicating cell.
Down-regulation of ribosomal proteins
Hu et al. [28] showed a 98% decrease in protein synthesis
using 35S-met pulse labeling experiments with microaer-
ophilic cultures (50 days in unstirred, screwcap vials) sim-
ilar to the Wayne model [8]. The transcriptional
experiments collected here are consistent with this result.
Over half of the 55 30S and 50S ribosomal-protein genes
encoded by the M. tuberculosis genome are down-regu-
lated. Fig. 3 also illustrates that information pathways
(including transcription and translation) show significant
down-regulation.
Isoprene biosynthesis
Fig. 5 shows the isopentenyl-pyrophosphate biosynthetic
pathway in M. tuberculosis. Of all the metabolic pathways
we examined, this pathway showed the most consistent
up-regulation of genes across the entire pathway. One of
the uses of isopentenyl-pyrophosphate is the biosynthesis
of decaprenyl phosphate, which is needed for cell wall
construction (see Discussion). Consistent with this role is
the result that insertion into dxs1, ispD, ispE and ispF show
inhibition in the in vitro growth experiments [13]. Signifi-
cant synthesis of cell wall components is also needed to
survive the multiple stresses inside the macrophage
phagosome. Nearly all of genes in the pathway are up-reg-
ulated in the mouse macrophage model [29]. Also con-
tributing to the high expression scores are the later time
points in the long terms experiments [30,31]. This may
reflect the continuing need to maintain membrane integ-
rity during long term survival.
Discussion
Our analysis suggests that during dormancy M. tuberculosis
performs limited protein synthesis. The pathogen spends
its available resources on maintaining cell wall, mem-
brane potential and genome integrity as well as resisting
host defenses.
The main objective of our analysis was to develop a prior-
itized list of genes that might be suitable targets for drugs
effective against non-replicating bacilli (Fig 1, Step 4). The
foremost assumption is that genes that are highly
expressed in a number of experimental situations are
Histogram of the distribution of upregulated and downregu- lated gene scores for the entire genome overlaid with the  distribution from the devR regulon (A) and the relA regulon  (B) Figure 4
Histogram of the distribution of upregulated and downregu-
lated gene scores for the entire genome overlaid with the 
distribution from the devR regulon (A) and the relA regulon 
(B).
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important for persistence of non-replicating M. tuberculo-
sis. This was not an absolute criterion but pathways or
multimeric complexes in which only a single gene was up-
regulated were judged to be less important or anomalous
results and, therefore were considered to be lower priority
targets. The knockout experiments address a fundamen-
tally different question than do the dormancy experi-
ments (e.g. replication versus non-replicative survival).
The focus of this analysis is on the non-replicative state.
Targets that show both up-regulation in the dormant state
and inhibit growth are certainly more interesting, but it
may well be the case that genes required for survival in the
non-replicating state have no effect on growth. As an
example, Rengarajan et al. found that genes expressed
under hypoxic or low nutrient conditions simulating the
granuloma environment, are not necessarily essential for
intracellular growth in macrophages [12]. In bacteria,
growth essential genes are often constitutively expressed
while virulence and environmental response genes tend
be highly regulated yet essential during those periods of
high induction. Thus one would expect that different
groups of genes play distinctive roles, and have transient
importance for viability, in the non-replicative versus rep-
licative phases of the bacterium's life cycle.
Here we discuss the relative tractability of proposed dor-
mancy phase modulated genes and pathways as drug tar-
gets for the eradication of dormancy phase M. tuberculosis.
The individual genes and scores discussed below are listed
in Additional file 4. Since not every gene in a particular
pathway scored highly, we included additional low scor-
ing pathway proteins in order to provide context for tar-
geting particular pathways.
devR regulon and other regulatory systems
An effective immune response that halts disease progres-
sion typically results in formation of granulomas. It is in
these granulomas that the non-replicative bacilli are
believed to reside [32,33]. Based on the nature of the gran-
uloma, it is very likely that the non-replicating bacilli are
surviving in an hypoxic environment. Granulomas are
necrotic, avascular lesions that are walled off from the
immune system. They are made up of caseous (chalky)
centers and contain dead macrophages, T-cells and the
tubercular bacilli [34,35]. This environment also has ram-
ifications for the nutrient supply.
The results here and elsewhere [18,19,36,37] clearly show
that the devR regulon (also known as the dosR regulon) is
a significant regulator of genes in response to the experi-
mental stressors of hypoxia and nitric oxide. This, com-
bined with the production of nitric oxide by host immune
cells and the likely hypoxic nature of the granuloma,
makes a strong, albeit circumstantial, case for this regulon
to be a primary trigger in the metabolic shiftdown to
achieve the non-replicative state.
Additional evidence comes from Malhotra et al. [38]
where guinea pigs were infected with wild type H37Rv M.
tuberculosis and a devR::kan mutant. After 47 days the lungs
of the animals infected with the mutant strain showed
small granulomas (<20%) and a normal lung architec-
ture; the lungs of the animals infected with wild type
showed partial to complete destruction with granulomas
taking over 45–85% of the lung. Using the less virulent
strain Mycobacterium bovis BCG, Boon and Dick showed
that a devR::kan mutant grew at the same rate as wild type
during the aerated phase of the Wayne model, but had a
1500 fold decrease in viability during the 5 week hypoxic
phase [39]. Mice lacking iNOS are rapidly killed by M.
tuberculosis, whereas mice with functional iNOS yield
chronic infections. One interpretation is that nitric oxide
activates devS and devR, resulting in metabolic downshift-
ing and latent infection. Without the nitric oxide signal,
the regulon is not upregulated and cell division continues
until the host is killed [40,41].
devS/devT devR two component sensor
Two component response regulator systems are found in
bacteria, fungi, and plants [42,43] and are already being
exploited as new antibiotic targets [44,45]. These systems
consist of a sensor kinase (component 1) which auto-
phosphorylates histidine, then transphosphorylates a
conserved aspartate of its cognate transcriptional regula-
tor (component 2). M. tuberculosis has eleven complete
The two biosynthetic pathways for isopentenyl-pyrophos- phate biosynthesis Figure 5
The two biosynthetic pathways for isopentenyl-pyrophos-
phate biosynthesis. The gene products (enzymes) from the 
M. tuberculosis genome presumed to catalyze each transfor-
mation are specified by the Rv numbers. Enzymes for which 
there is not a relevant orthologue in the M. tuberculosis 
genome are labeled as missing. [119] [76].
pyruvate + D-glyceraldehyde-
3-phosphate
1-deoxy-D-xylose-5-phosphate
Rv2682c
Rv3379c
Rv2870c
acetyl-CoA + acetoacetyl-CoA 2-C-methyl-D-erythritol-4-phosphate
Rv3582c missing
3-hydroxy-3-methylglutaryl -CoA 4-diphosphocytidyl-2-C-methyl-D-erythritol
Rv1011 missing
4-diphosphocytidyl-2-C-methyl-
D-erythritol-2-phosphate mevalonate
Rv3581c missing
2-C-methyl-D-erythritol-
2,4-cyclodiphosphate
mevalonate-5-phosphate
Rv2868c missing
1-hydroxy-2methyl-
butenyl-4-diphosphate mevalonate-5-diphosphate
isopentenyl diphosphate
dimethylallyl diphosphate
Rv1745c
Rv1110
Rv3382c 
missingBMC Infectious Diseases 2007, 7:84 http://www.biomedcentral.com/1471-2334/7/84
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systems and seven orphans belonging to sensor kinase
and response regulator families [17]. It has been shown
that recombinant sensor kinases devS and devT autophos-
phorylate to stable phosphoproteins, but rapidly
transphosphorylate  devR  [46-48], confirming these as
members of the two component family. Additionally sev-
eral papers have identified devS/devT devR as a strong can-
didate for therapeutic intervention [15,47,49,50,6,51,52].
The results collected here are consistent with these analy-
ses. It interesting to speculate that this approach may work
not by killing M. tuberculosis directly, but by forcing them
out of the non-replicative state, [2] leaving them suscepti-
ble to the usual anti-microbial agents. If the regulatory
system having significant control over non-replicative
metabolism were disrupted, this could lead to exit from
the non-replicative state or a metabolic catastrophe. Ide-
ally the cell would suffer unregulated expression with
insufficient resources from which it could not recover.
Paving the way for further work are recent papers which
describe a validated high-throughput screening assay [49].
and x-ray crystal structures of the C-terminus of devR, with
and without DNA bound. [50]. A fluorescence polariza-
tion assay has been described for binding of component 2
to its cognate DNA sequence [53].
A bifunctional inhibitor or a combination of compounds
may be necessary to attack the sensor kinase since it took
knockouts of both devS and devT to prevent phosphoryla-
tion of devR after 2 h of hypoxia [46]. Blocking devR bind-
ing to its cognate DNA-binding sites might require a less
complex therapeutic strategy. The ATP site here and in the
universal stress proteins and mprA, mprB regulators
(below) offers the opportunity to take advantage of the
growing expertise in development of kinase inhibitors
[54].
Universal stress proteins
Universal stress proteins (USPs) are a family of proteins
that are produced by bacteria in response to a range of
environmental stressors and cause a significant change in
metabolism [55]. In our analysis, five of the eight Usp
genes in the M. tuberculosis genome score in the upper 5%
of expression results. The exact function of USPs in TB
pathogenicity is not fully understood although studies in
other species suggest they likely play a key cellular role.
The function of UspA from E. coli has been characterized
by Nyström et al. [56]. Increased expression of UspA to
physiological levels caused a global change in protein
expression and decreased cell growth on minimal media,
and decreased expression (via  insertional inactivation)
results in a disruption of glucose metabolism and excre-
tion of acetate. The authors proposed that UspA may have
a direct effect on alteration of the flux of carbon through
the primary metabolic pathways during arrested growth
[57]. UspA has autophosphoryating activity [58] but is
also phosphorylated by other proteins, including TypA
[59]. If the parallels to other species hold, USPs in M.
tuberculosis might affect the regulation of primary carbon
metabolism, cause changes in the expression of a signifi-
cant number of proteins, and generally modulate the met-
abolic shift to stasis. All eight of the Usp members found
in M. tuberculosis show the ATP binding signature found in
MJ0577 [60], for which there is a crystal structure with
ATP bound [61]. Since ATP-competitive inhibitors are
well-known, the USPs are very attractive targets. There is
also a crystal structure of Rv1636 (unfortunately the low-
est expressing member) opening up rational design
approaches.
mprA, mprB two component sensor
A second two component sensor kinase/transcriptional
regulator, mprA/mprB, also appears to be involved in per-
sistent infections. Biochemical characterization of the
phosphorylated intermediates has established this as a
bona fide two-component system [62]. Knockout experi-
ments show a survival disadvantage in long term infection
in mouse models, though the effect is tissue specific. Mice
co-infected with wild type H37Rv M. tuberculosis and an
mprA::Kmr mutant were analyzed after 147 days. In the
spleen, 2% of the culturable M. tuberculosis were mutants,
in the lung, 25% were mutants, and in the liver, 75% were
mutants [63].
Bacterial sigma factors play a role in transcriptional initia-
tion. A recent review summarizes the current state of
knowledge of the Mycobacterium  family [64]. Several
sigma factors are up-regulated (sigB, sigE, sigH, and sigF)
and there is a tantalizing functional connection between
the Bacillus subtilus sigma factor sigF involved in sporula-
tion and the M. tuberculosis homolog [65,66]. Cappelli et
al. show sigG upregulation after 7 days in human macro-
phages, suggesting a role in adjusting transcription to sur-
vival inside the macrophage [67]. However, any novel
anti-TB strategy based on the targeting of transcriptional
components such as sigma-factors, would need to demon-
strate some advantage over current rifampin therapy
which also disrupts transcription through the inhibition
of RNA polymerase activity. The mprA/mprB two-compo-
nent system has been shown to directly regulate sigB and
sigE [68]. The effect of the mprA::Kmr mutant was not as
dramatic as could be hoped for, but if the link with the
sigma factors and the metabolic shutdown in sporulation
is substantiated, then the result of inhibition of mprA or
mprB may be to reactivate M. tuberculosis.
relA regulator/phosphorylase
Under conditions where amino acids or carbon are limit-
ing, bacteria shift their metabolism via a series of well-
studied pathways known as the stringent response. Dis-
ruption of the stringent response is a potential mecha-BMC Infectious Diseases 2007, 7:84 http://www.biomedcentral.com/1471-2334/7/84
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nism to force M. tuberculosis to exit from dormancy phase.
In M. tuberculosis, the stringent response is mediated by
relA (aka RelMtb, Rv2583c) which synthesizes and degrades
hyperphosphorylated guanine nucleotides that in turn
affect RNA polymerase and gene expression [69-72]. Dahl
et al. compared relA knockouts with wild type under nutri-
ent sufficient and starvation conditions and analyzed the
expression patterns [69]. They concluded that relA glo-
bally down-regulates the cellular translation apparatus,
including 54 of 58 ribosomal proteins. Fig. 4B shows the
comparison of the expression profile of the down-regu-
lated genes for the whole genome and the genes in Dahl
et al. shown to be differentially regulated during starva-
tion in M. tuberculosis wildtype but not in relA deletion
mutants. relA showed a modest change in up-regulated
expression, scoring 3.8, not far from the genome median
of 3.1, and the positive scores do in fact come from the
starvation conditions (Additional file 4). Hasan et al. [15]
similarly scored relA low as a persistence target. However,
despite the low score we feel that relA should be a good
therapeutic target, especially if it disrupts the regulation of
protein synthesis. It seems probable that devR and relA are
working in concert, each responding to different environ-
mental cues, to achieve the metabolic downshift to the
non-replicative state.
C2 metabolism
The dual stresses of an unbalanced nutrient pool and
hypoxia place significant demands on the regulation of
metabolites through the two-carbon pathways. Transcrip-
tional analyses [29,73] suggest M. tuberculosis survives in
the host on a nutrient pool rich in fatty acids and poor in
carbohydrates [17,74]. Fatty acids are broken down to
acetyl-CoA by the five-step beta-oxidation pathway. M.
tuberculosis has 34 acyl-CoA synthases, 34 acyl-CoA dehy-
drogenases, 21 enoyl-CoA hydratases, six 3-hydroxyacyl-
CoA dehydrogenases, and six acetyl-CoA C-acetyltrans-
ferases. There are over 250 lipid metabolizing enzymes in
M. tuberculosis compared to 50 in E. coli, which underlines
the importance of fatty acids as a nutrient source for this
bacillus [17]. The postulate has been put forward that the
main storage molecule for fatty acids are triacyl glycerols
and 15 M. tuberculosis genes showed triacylglycerol syn-
thase activity [75]. A knockout of the most active and
highly upregulated synthase, Rv3130c, named tgs1, com-
pletely eliminates accumulation of triacyl glycerols in
hypoxic M. tuberculosis. As the authors suggest, inhibition
of tgs1 could lead to starvation of non-replicative cells, but
may be compromised by the redundant activity of the
other synthases.
Pantothenate biosynthesis
Acetyl-coenzyme A (Ac-CoA) is a central intermediate in
primary metabolism with roles in the TCA cycle as well as
fatty acid and amino acid biosynthesis. The flux of carbon
through Ac-CoA is particularly critical to non-replicating
M. tuberculosis. Fatty acids, via breakdown to Ac-CoA and
use of the glyoxylate shunt, provide the carbon for carbo-
hydrate synthesis and acetyl-coenzyme A appears to be the
gate through which much of the utilized carbon pool
must pass. The M. tuberculosis membrane, being rich in
unusual carbohydrates [76,77], is likely critically depend-
ent upon this carbon flux through Ac-CoA for the mainte-
nance of its integrity.
Targeting coenzyme A biosynthesis should disrupt the
flux through several pathways. Supporting this notion are
inhibitors of pantothenate kinase that suppress the
growth of the low GC Gram-positive bacterium, Staphylo-
coccus aureus, in a typical MIC assay [78]. However pan-
tothenate biosynthesis knockouts in M. tuberculosis in
mouse infection experiments suggest the operation of
some salvage mechanism [79]. PanC and panD are two of
the five genes needed for de novo biosynthesis. A double
deletion mutant was constructed and tested in immuno-
compromised SCID and normal BALB/C mice. In both
strains the panCD knockouts show greatly attenuated vir-
ulence. The SCID mice injected with the double mutant
live seven times longer than those injected with the wild
type H37Rv M. tuberculosis. The double mutant does not
kill any of the BALB/c mice, even after 1 year. Yet in both
cases there is significant bacterial load. The lungs of the
SCID mice eventually reach >108 cfu, likely the cause of
death. The lungs of the BALB/C mice reach almost 106 cfu
after 2 weeks and show severe, diffuse granulamatous
pneumonia; the infection is slowly cleared over the next
months. The spleen and liver show similar pathologies.
The mechanism that allows this persistence is not clear.
The panCD knockouts are able to grow in SCID and BALB/
C mice yet have greatly attenuated virulence. The authors
suggest an unidentified permease is salvaging enough
pantothenate to survive but not enough to cause disease.
In order for a pantothenate biosynthesis inhibitor to be
effective, the supply of exogenous pantothenate must be
exhausted. This is possible since, as mentioned above, the
granulomas formed in the mouse do not show the central
caseating necrosis found in the human lung. Testing the
panCD knockout in a model that closely replicates the
human granuloma is critical to the validation of this path-
way as a potential drug target.
Redox balance
Under hypoxic conditions there is a lack of terminal elec-
tron acceptors and M. tuberculosis must reoxidize reduced
metabolites to maintain viability. Maintaining redox bal-
ance, especially in the face of heavy use of fatty acids, is
critically dependent upon the fate of the acetyl unit as it is
either oxidized for energy, utilized for biosynthesis, or
shunted off to intermediates to hold reducing equivalents.BMC Infectious Diseases 2007, 7:84 http://www.biomedcentral.com/1471-2334/7/84
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Eventually some of these reduced compounds must make
their way to terminal electron acceptors.
Knockouts of the genes encoding two isocitrate lyase iso-
forms (icl1 and icl2) have shown that disruption of reac-
tions close to or within these primary metabolic steps are
effective and it has long been noted as a promising thera-
peutic target [74,80]. Its effectiveness in knockout experi-
ments and with a prototype inhibitor (3-nitropropionate)
is likely due to its role in enabling the utilization of the Ac-
CoA pool for carbohydrate synthesis [81,74,80,82]. The 3-
dimensional structure of the enzyme will also aid the dis-
covery of inhibitors of ICL [83].
Genes for PEP (phosphoenolpyruvate) carboxykinase and
a citrate synthase, both involved in carbohydrate metabo-
lism, are also up-regulated. Three genes are annotated as
citrate synthases, converting oxaloacetate and Ac-CoA to
citrate and CoA. Cit3 shows significant up-regulation and
could be an attractive target if the other two enzymes do
not provide a functional alternative. Malate dehydroge-
nase (mez), another enzyme intimately involved in pri-
mary metabolism, shows modest up-regulation.
Alanine dehydrogenase has been suggested to be impor-
tant both for the production of alanine (utilized in pepti-
doglycan) and for maintenance of the NAD pool [84,85].
The kinetic behavior of the enzyme strongly suggests that
its primary function is to catalyze the formation of
alanine. The M. smegmatis alanine dehydrogenase is also
suggested to have glycine dehydrogenase activity [86]. If
this holds for M. tuberculosis, inhibition of this enzyme
would also disrupt the glyoxylate pool. The potential
effect on a peptidoglycan precursor, redox balance, and
carbohydrate synthesis coupled with its upregulation
make this enzyme a viable target. The protein was also
identified in a proteomics analysis of the Wayne model
[87].
Another strategy to disrupt block redox balance is to attack
the key carrier of reducing equivalents: NAD(P)+. Taking
into account both avoidance of enzymes with close
human orthologues and inclusion of those genes with
high expression scores, the best target appears to be nadR.
NadR is a bifunctional enzyme with nicotinamide-nucle-
otide adenylytransferase and ribosylnicotinamide kinase
(RNK) activities.
Respiratory chain
Another drug targeting opportunity created by hypoxia is
the need for M. tuberculosis to utilize alternate terminal
electron acceptors as the final step of respiration. Wayne
and Sohasky [2] have proposed that nitrate is reduced by
a nitroreductase (narGHJ) and is then excreted by a nitrite
extrusion protein (narK1, narK2, narK3). This scheme is
supported by the transcript levels of proteins in the respi-
ratory chain. [27] Knockouts of narG in a SCID mouse
model with M. tuberculosis BCG show a decreased viru-
lence of the mutant compared to wild type [88], leaving
open the possibility that blocking nitrate reduction could
be effective against a truly hypoxic adapted M. tuberculosis.
Nitrate reduction is controlled by the strongly up-regu-
lated  narK2, also a member of the devR  regulon [89].
Sohaskey has shown that the presence of narK2 is respon-
sible for the 75 fold difference in nitrite synthesis between
actively growing, oxygenated cultures and hypoxic, non-
replicative bacilli. This represents another strategy to take
advantage of hypoxia.
Knockouts of the 'fused reductase' narX have no effect so
this gene appears to be inactive [90]. Additionally, three
genes which are significantly up-regulated contain the
nitroreductase ortholgous group, COG0778 (Rv2032
(acg), Rv3131 and Rv3127). However the lack of nitrate
reductase activity after a narG  knockout argues against
these as respiratory inhibition targets [90].
Moving up the reaction path leads to the proteins in the
respiratory chain. There are several redox proteins that
have high to moderate up-regulation scores and are likely
involved as alternate electron carriers in the hypoxic envi-
ronment: fumarate reductase (frdA), probable NAD(P)H
dehydrogenases (Rv3054c, Rv0082, Rv1812c, and
Rv1854c), and ferridoxin (fdxA). Ferridoxin is the most
significantly up-regulated of the low-redox potential elec-
tron carriers [9]. Recent studies show that phenothiazines
inhibit NADH:menaquinone oxidoreductase (Rv1854c,
Rv0392c) and stop growth in acute models [91,92]. This
class of inhibitor may force the respiratory chain into an
oxidized state and M. tuberculosis to behave as if it were in
an aerobic environment. The potential of this mechanism
to signal the bacilli to switch its metabolism back to the
replication, hence more vulnerable to existing antibiotics,
is an intriguing therapeutic approach.
The liability with the respiratory chain targets is the poten-
tial for redundancy. It is unknown which or how many
enzymes to inhibit for a lethal blockade. However, as
mentioned above, inhibition may not be the best
approach. Uncoupling electron transfer with generation
of the proton motive gradient or phosphorylation of ATP
should be rapidly lethal. Rv1812, Rv1854c and the fuma-
rate reductase complex are believed to be components of
the oxidative phosphorylation chain and could take
advantage of the uncoupling strategy. The human ortho-
logue to fumarate reductase, NP_004159, shows 35%
identity and 51% similarity to the M. tuberculosis enzyme
at the amino acid level, so there is the potential for toxicity
that would have to be addressed.BMC Infectious Diseases 2007, 7:84 http://www.biomedcentral.com/1471-2334/7/84
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Downregulation of ATP synthesis
Since M. tuberculosis appears to have limited available ATP
in dormancy phase, targeting ATP synthesis also looks to
be a promising strategy. The newly discovered diarylyqui-
noline inhibitor of the ATP synthase proton pump [93]
could be a valuable tool for establishing whether this
approach would be effective against non-replicating cells.
Compounds with similar modes of action as 2,4-
dinirophenol that uncouple ATP synthesis from proton
movement may also work provided they could be made
selective for M. tuberculosis [94,95]. It is unclear whether
targeting processes that utilize ATP would result in cell
death. It is possible that they are occurring so slowly
already (due to low availability of ATP) that inhibition
would have a minor effect. An alternative approach would
be to deplete available ATP stores. A compound that
caused a futile ATP cycle could be very effective in killing
dormant cells. For example if an ATP dependent trans-
porter could be reduced so as to be only 1% efficient, this
could drain the ATP pool and leave the bacterium unable
to recover.
Sulfate transport and metabolism
Wooff et al. [96] have studied sulfate transport knockouts
in M. bovis in detail. The sulfate transporter is made up of
the proteins from cysA1, cysT, cysW, and subI. Transposon
insertions into cysA1 or subI yield methionine auxotrophs
completely unable to import sulfate which indicates that
cysA1 is the sole sulfate transporter. They conclude that
cysA2, and cysA3 are in fact thiosulfate sulfurtransferases.
M. tuberculosis has two additional genes that are up-regu-
lated and also annotated as possible sulfate transporters
(Rv1707 and Rv1739c); it is not known whether these are
active.
Wooff et al. also inoculated BALB/c mice with the cysA1
auxotroph and found no difference in growth compared
to wild type, suggesting that the mutant was able to sur-
vive well using exogenous sources of methionine.
Recently, it has shown that M. tuberculosis can convert
methionine into cysteine [97]. The expression results ana-
lyzed here imply that sulfur is deficient within M. tubercu-
losis. Whether this situation can be remedied by
scavenging methionine is likely dependent upon the
nutrient pool available in the local environment of the
granuloma.
Once sulfate is transported in the cell, it is activated by
conversion into adenosine 5'-phosphosulfate (APS) and
3'-phosphoadenosine 5'-phosphosulfate (PAPS). The
genes for these enzymes (cysD and cysN) are significantly
up-regulated. M. tuberculosis CysN, also known as cysNC,
contains two fused activities, sulfate adenylyltransferase
(cysN) and adenylylsulfate kinase (cysC) [98]. These genes
have been cloned and the recombinant enzymes are func-
tional and produce PAPS from sulfate, ATP and GTP
[98,99]. Recent work has shown that in M. tuberculosis
APS, not PAPS, is utilized for cysteine and methionine
biosynthesis [100]. Several genes in this pathway are up-
regulated: cysD, cysN (transferase), metC, and cysK2. The
same issue arises here as with the transporters: will
methionine salvage outflank the inhibitory blockade? As
above this remains to be tested with a necrotic granuloma.
There is an additional possibility, however. Another role
of sulfate is in the synthesis of sulfated lipids. (See refer-
ence [101] for a review of sulfate metabolism in M. tuber-
culosis.) Sulfated lipids are synthesized from PAPS and
known targets to date are cysC  (kinase domain) and
Rv1373 [100]. Inhibition of sulfolipid synthesis may be
effective in the early phases of infection [102]; it is not yet
known what the role of sulfated lipids is in persistent
infection, but the hope is that the up-regulation of the
genes for APS, PAPS and sulfolipid synthesis are indicative
of a critical function.
Other transporters
CtpF and ctpG are annotated as probable ATP dependent
cation transporters. If the annotations are in fact correct
then these are promising targets. They have the advantage
of avoiding the salvage problem above and opening up
the opportunity for futile hydrolysis of ATP. However, the
high similarity of these two proteins with human
orthologs could provide challenges in the development of
M. tuberculosis selective inhibitors (Additional file 4).
Downregulation of protein synthesis
Rifampin, a transcriptional inhibitor, is one of the few
drugs effective against M. tuberculosis in the NRP-2 phase
of the Wayne model [103]. Rifampin thus serves as an
important benchmark: it has efficacy against persistent M.
tuberculosis, so any strategy that does not have a rationale
for a shorter therapy should not make the list of new tar-
gets. We put proteins synthesis inhibitors into this cate-
gory. This is borne out in clinical trials: streptomycin, an
inhibitor of protein synthesis the binds the 30S ribosome,
is not as effective as rifampin throughout a long treatment
period [104,35].
Ribonucleotide reductase
The effectiveness of inhibiting ribonucleotide reductase in
actively growing cells is shown by Dawes et al. [105]. The
large and small subunits of the type Ib reductase is
encoded by nrdE  and  nrdF2, respectively. Knockout of
nrdF2 is lethal, both validating this gene as a target, and
showing that neither nrdF1 nor nrdZ could substitute. In
contrast to our analysis (which show up-regulation of all
the nrd genes), quantitative RT-PCR studies of nrdEF2 in
the Wayne model shows a 10 fold decrease in expression
from log phase to NRP-1, followed by a 2–3 fold increaseBMC Infectious Diseases 2007, 7:84 http://www.biomedcentral.com/1471-2334/7/84
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from there as the cells progress into NRP-2. Dawes et al.
also found surprising results with knockouts of nrdZ
which encodes a putative class II reductase that is also up-
regulated by devR. The expected scenario where nrdEF2 is
down-regulated and nrdZ takes over during hypoxia was
not observed. NrdZ knockouts had no effect on survival in
the Wayne model or in B6D2/F1  mice, even after 14
months. So it appears that nrdEF2 is still supplying the
needed pool of deoxyribonucleotides.
With regard to the main focus of our analysis, the real
question is one of rate: is the rate of DNA damage to non-
replicating M. tuberculosis high enough so that blocking
repair will shorten therapy? The main impetus for devel-
oping ribonucleotide reductase inhibitors will certainly be
to kill actively dividing cells. They may have the addi-
tional benefit of preventing cells from reactivating or leav-
ing cells with a damaged genome to die.
Isoprene biosynthesis
As shown in Fig. 5, M. tuberculosis solely utilizes the pyru-
vate/glyceraldehyde phosphate pathway for isopentenyl-
pyrophosphate biosynthesis and lacks the mevalonate
pathway found in eukaryotes and some low GC Gram
positive organisms [76]. Isopentenyl-pyrophosphate is a
precursor in the synthesis of decaprenyl phosphate. Deca-
prenyl phosphate is a 50-carbon lipid that has at least 2
functions in the productions of the mycolic acid-arabi-
nogalactan-peptidoglycan complex of the cell wall [76].
Nearly all of the enzymes of the cell wall biosynthetic
pathway show low up-regulation scores (typically 0 – 4; as
an example, murA, murB, murC, murD, murE, murF, and
murG score 1.5, 0, 0, 2.2, 3.9, 0.3, and 3.8 respectively).
Cell wall biosynthesis is already targeted by isoniazid
(which is most effective in the first few days of TB treat-
ment) [104], and the expression scores are low, so the
argument can be made that targeting the cell wall is not
interesting in the context of attacking non-replicating M.
tuberculosis. However a recent review argues that mainte-
nance of the membrane in persistent M. tuberculosis is
important for long term viability, but the biochemical
mechanisms are very difficult to determine [106]. The
function of decaprenyl phosphate as a carrier molecule
may be more disruptive to downstream processes. We
believe that this coupled with the knockout and up-regu-
lation seen in the long term experiments makes this path-
way a viable target.
Other Targets
lysine-ε-aminotransferase
Lysine is biosynthesized starting with aspartate and pyru-
vate, the so-called diaminopimilate pathway. The data
here shows that this pathway is significantly downregu-
lated. An altenative pathway exists in fungi, which starts
with Ac-CoA and 2-keto-glutarate. The final enzyme in the
fungal pathway, lysine-ε-aminotransferase, has been iden-
tified in M. tuberculosis while the other nine enzymes are
either absent or yet to be annotated. Lysine-ε-aminotrans-
ferase is also found in several bacterial and fungal species.
Its role in non-replicative metabolism is not clear. The
high up-regulation score makes this an intriguing poten-
tial target. A crystal structure of this enzyme has recently
been reported which could facilitate rational drug design
[107].
Membrane protease regulating envelope composition
Rv2869c has been identified as an intramembrane cleav-
ing protease (iCLIP) that regulates the composition of
mycolic acids and some phosphatidylinositol manno-
sides in the M. tuberculosis cell envelope, as well as having
transcriptional effects on other lipid metabolizing
enzymes [108]. A deletion of the protease had no effect on
cell counts in infected mice after 24 h indicating that it is
not critical for the acute phase of infection, however after
22 weeks the bacterial load in the lung was down 10,000
fold compared to wild type. The up-regulation score for
this enzyme is not even at the genomic median, but the
knockout results, as well as the lack of a closely related
human homolog, make a compelling case for this as a
therapeutic target.
Chaperonins/HSP
Wayne and Sohaskey have suggested that the decreased
effectiveness of rifampin in the non-replicative state in the
Wayne model could be due in part to the stabilizing effect
of the chaperonins [2]. Thus a combination therapy of
rifampin and a chaperonin inhibitor has the potential to
shorten the therapeutic regimen. Alpha-crystallin 1
(Rv031c,  hspX,  acr1) has a large molecular chaperone
domain [24] and is among the genes most highly induced
in the devR regulon. The biology of alpha-crystallin 1 is
complex as evidenced by the effect on growth when the
genes are knocked out. Recent work has shown more
rapid initial growth and increased colony counts in mouse
lung and spleen in acr1 knockouts [109,110]. These find-
ings suggest that acr1 has a role in the growth rate both
during the initial stage of infection and long term persist-
ence. The role of acr1 as a growth modulator raises the
attractive possibility that interfering with its function
could cause a beneficial switch to active replication.
The second of two alpha-crystallins in M. tuberculosis,
encoded by the gene acr2, has one of the highest expres-
sion scores, consistent with Stewart et al. [111] where it
was up-regulated at every stage of infection. A knockout of
the acr2 gene had no significant effect on bacterial load in
the mouse lung or spleen, though the mice did not expe-
rience as significant weight loss as those infected with wild
type. An interesting experiment would be the effect ofBMC Infectious Diseases 2007, 7:84 http://www.biomedcentral.com/1471-2334/7/84
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dual knockouts of both acr1 and acr2 genes in the pres-
ence of rifampin.
M. tuberculosis has other chaperonins; groEL1 and groEL2
show moderate up-regulation scores and should also
work in concert with rifampin. A concern with these two
proteins is that there are reasonably close mammalian
orthologues. A human chaperonin (NP_955472) has
41% identity and 65% similarity with groEL1, and groEL2
(for which there is a crystal structure [112]) is 46% iden-
tical and 68% similar to another human chaperonin
(NP_002147). Again there is the problem of redudancy,
with at least four proteins capable of stabilizing proteins
during persistence.
Conclusion
Here we integrated a number of data sets that utilized
DNA microarrays covering spectrum of experimental con-
ditions into a single analysis of dormant phase M. tubercu-
losis. Drug targets to specifically attack non-replicative
bacilli emerging from our analysis were several regulatory
elements that have the potential to force M. tuberculosis
back into replicative mode. Other targets take advantage
of the presumed hypoxic environment to state to disrupt
redox balance, an altered respiratory chain, or the likely
scarcity of ATP.
A recent paper was able to examine the transcriptional
profile of M. tuberculosis from human lung samples [113].
The patients had active disease and were on chemother-
apy so some of the granulomas were breaking up as part
of reactivation. As a result a fraction of the cells were
exposed to oxygen in vivo and possibly post excise as the
resected samples were exposed to air. This could explain
the up-regulation of a number of genes involved in aero-
bic metabolism. While a very important study we believe
that these samples may be quite heterogeneous and might
not entirely reflect the dormant phase.
The advent of large scale genomics covering not only the
genomes of multiple bacterial species but also various
strains within a pathogenic species, has lead to the appli-
cation of comparative genomics analysis to derive lists of
high priority gene targets. Genes can be ranked by a
number of different criteria such as divergence from
human genes; essentiality for both in vitro and infectious
viability; homology across known pathogens; importance
to pathogenic life cycle; tractability to small molecule
inhibitors and so on. In reality, some seemingly obvious
criteria have little pharmacological relevance. For exam-
ple, the antibiotic rifampicin targets DNA-directed RNA
polymerase which is highly conserved across all species
including prokaryotes and humans yet it is a key member
of the anti-TB compound quartet. While bioinformatics
derived lists of prioritized genes can provide important
starting points for new target discovery and to help organ-
ize genomic data [15], decisions on which TB drug devel-
opment strategies to pursue requires additional context
about pathogen biology, biochemistry, pharmacology
and pathogenicity. Using this approach, we have sug-
gested several potential drug development strategies
against dormant phase M. tuberculosis which target key
biosynthetic pathways.
Methods
The data sets and scoring weights compiled for this analy-
sis are listed in Table 1. A zero to five scoring system was
developed that utilized both the relevance of the experi-
mental conditions to the dormant state and the rank order
of expression.
The maximum score for a particular experimental dataset
was adjusted based on our judgement of relevance to the
clinical occurrence of dormancy phase M. tuberculosis
infections. For studies with multiple time series sampling,
increasing weight was given to later time-points samples.
For example Wayne and Hayes [8] have shown two phases
of metabolic shiftdown: NRP-1 (characterized by toler-
ance to metronidazole, greatly slowed growth, and thick-
ening of cell walls) and NRP-2 (characterized by
sensitivity to metronidazole and absence of growth)
[114]. In order to take into account both phases, but
weigh the scoring toward NRP-2, which is likely more rel-
evant to clinical dormancy, genes in NRP-2 received
higher scores (e.g. 5 points maximum) than genes in NRP-
1 (e.g. 2 or 3 points maximum).
Once the maximum score was set for a particular experi-
ment, the genes were ordered from highest to lowest
based on expression ratio (fold expression in the experi-
mental condition versus cells in log-phase liquid culture).
The highest scoring gene received the maximum score
(listed in column 3 of Table 1. (e.g. 5, 4 ..., 1 point)). The
score was decreased by 0.005 points for each gene in order
until zero, or the end of the data set was reached. Thus
when the maximum score was 4 points, the 100th ranked
gene would receive a score of 3.500. For a maximum score
of 5 points, 1000 genes or 25% of the MTB genome
received a score. For experiments where data from multi-
ple time points were collected, the maximum score across
all time points was used as the final score.
For example the up-regulation score of Rv3133c, devR,
was calculated by summing the maximum scoring time-
point (underlined) from the following studies
(score:timepoint):
Hampshire et al., 2004 [30] (0:18 d, 0:49 d, 3.57:62 d,
0.185:76 d);BMC Infectious Diseases 2007, 7:84 http://www.biomedcentral.com/1471-2334/7/84
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Muttucumaru et al., 2004 [115] (1.915:7 d, 3.915:14 d);
Voskuil  et al. 2004 [31] (0:4 d, 1.875:6 d, 1.895:8 d,
2.860:10 d, 2.815:12 d, 3.820:14 d, 3.07:20 d, 0:30 d,
3.325:80 d);
Schnappinger et al. 2003 [29] (0:24 h (naïve, ampl.), 0:24
h (naïve, oligo.), 0:48 h (naïve, ampl.)), 4.870:24 h (acti-
vated, ampl.), 4.800:24 h (activated, oligo.), 4.185:48 h
(activated, ampl.).
In the remaining 3 studies [116-118]), this gene scored
zero. Therefore, the up-regulation score of Rv3133c, devR
equaled 16.175.
The scores for down-regulated expression were collected
in a similar fashion, except that genes were ordered from
lowest to highest and scores were negative. For the trans-
poson-based knockout experiments, genes which had no
effect on growth received a score of zero.
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